Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy

BackgroundThe aim of this study was to investigate the efficacy of bevacizumab (Bev) in reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung cancer brain metastases.MethodsA retrospective analysis was conducted on 44 patients with lung cancer brain metastases (70 le...

Full description

Saved in:
Bibliographic Details
Published in:Thoracic cancer 2023-11, Vol.14 (31), p.3133-3139
Main Authors: Hua, Yi‐Chun, Gao, De‐Zhi, Wang, Kuan‐Yu, Ding, Xiao‐Sheng, Xu, Wei‐Ran, Li, Yu‐Bin, Shi, Wei‐Wei, Sun, Shi‐Bin, Li, Xiao‐Yan
Format: Article
Language:English
Subjects:
bevacizumab
Brain cancer
brain metastases
Cancer therapies
Edema
Intracranial pressure
Kinases
Lung cancer
Magnetic resonance imaging
Metastasis
Monoclonal antibodies
Oncology
Original
Patients
peritumoral brain edema
Radiation therapy
radiotherapy
Steroids
Targeted cancer therapy
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThe aim of this study was to investigate the efficacy of bevacizumab (Bev) in reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung cancer brain metastases.MethodsA retrospective analysis was conducted on 44 patients with lung cancer brain metastases (70 lesions) who were admitted to our oncology and Gamma Knife center from January 2020 to May 2022. All patients received intracranial SRT and had PTBE. Based on treatment with Bev, patients were categorized as SRT + Bev and SRT groups. Follow-up head magnetic resonance imaging was performed to calculate PTBE and tumor volume changes. The edema index (EI) was used to assess the severity of PTBE. Additionally, the extent of tumor reduction and intracranial progression-free survival (PFS) were compared between the two groups.ResultsThe SRT + Bev group showed a statistically significant difference in EI values before and after radiotherapy (p = 0.0115), with lower values observed after treatment, but there was no difference in the SRT group (p = 0.4008). There was a difference in the distribution of EI grades in the SRT + Bev group (p = 0.0186), with an increased proportion of patients at grades 1–2 after radiotherapy, while there was no difference in the SRT group (p > 0.9999). Both groups demonstrated a significant reduction in tumor volume after radiotherapy (p 
ISSN:1759-7706
1759-7714
DOI:10.1111/1759-7714.15106